Arcus Biosciences has announced a clinical supply agreement with AVEO Oncology to evaluate its drug candidate casdatifan in combination with tivozanib for patients with advanced kidney cancer. The deal centers on testing whether the two therapies can be used together in this hard-to-treat setting.
Arcus described itself as a clinical-stage global biopharmaceutical company focused on developing differentiated molecules and combination treatments for cancer and inflammatory diseases. The new agreement fits that strategy by pairing casdatifan with an established oncology therapy as the company explores potential new options for kidney cancer patients.
Advanced kidney cancer remains an area of active research, with drugmakers increasingly studying combinations that may improve outcomes beyond single-agent treatment. By working with AVEO Oncology, Arcus is moving forward with a targeted evaluation of casdatifan alongside tivozanib in a patient population that continues to need additional therapies.
The announcement highlights continued industry interest in collaboration-based development, especially in oncology, where access to clinical supply can help accelerate combination studies. For Arcus, the agreement adds another step in its broader effort to build cancer treatment approaches around novel medicines and combination regimens.
